Ultragenyx Pharmaceu (RARE)

Mar 19, 2025, 5:00 PM EDT - 15 days ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 24, 2025, 4:30 PM EST - 5 weeks ago

Ultragenyx to Participate at Investor Conferences in March

Feb 13, 2025, 9:53 PM EST - 6 weeks ago

Ultragenyx Pharmaceutical Inc. (RARE) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 4:01 PM EST - 7 weeks ago

Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

Feb 6, 2025, 4:30 PM EST - 2 months ago

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update

Feb 5, 2025, 8:00 AM EST - 2 months ago

Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS

Jan 15, 2025, 2:05 PM EST - 2 months ago

Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside

Jan 12, 2025, 11:00 AM EST - 2 months ago

Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones

Jan 6, 2025, 4:30 PM EST - 3 months ago

Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 2:00 AM EST - 3 months ago

European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)

Dec 20, 2024, 3:00 AM EST - 3 months ago

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

Dec 19, 2024, 4:05 PM EST - 3 months ago

Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome

Nov 26, 2024, 4:30 PM EST - 4 months ago

Ultragenyx to Participate in Investor Conferences in December

Nov 12, 2024, 11:12 AM EST - 5 months ago

Ultragenyx: Ready For More Growth After Q3 Earnings Beat

Nov 9, 2024, 10:30 AM EST - 5 months ago

Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST's 17th Annual Global Science Summit

Nov 5, 2024, 10:40 PM EST - 5 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 4:01 PM EST - 5 months ago

Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update

Oct 3, 2024, 4:30 PM EDT - 6 months ago

Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

Sep 26, 2024, 8:00 AM EDT - 6 months ago

Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting

Aug 29, 2024, 4:30 PM EDT - 7 months ago

Ultragenyx to Participate in Investor Conferences in September

Aug 22, 2024, 10:22 AM EDT - 8 months ago

Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective

Aug 2, 2024, 6:07 PM EDT - 8 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Q2 2024 Earnings Call Transcript

Aug 2, 2024, 8:15 AM EDT - 8 months ago

Amlogenyx Inc. Closes Successful Seed Funding Led by GordonMD® Global Investments LP

Aug 1, 2024, 4:05 PM EDT - 8 months ago

Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update

Jul 22, 2024, 1:04 PM EDT - 9 months ago

Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst

IONS

Jun 13, 2024, 8:49 PM EDT - 10 months ago

Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Jun 12, 2024, 4:05 PM EDT - 10 months ago

Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jun 12, 2024, 4:00 PM EDT - 10 months ago

Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)

Jun 11, 2024, 5:47 PM EDT - 10 months ago

Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)

Jun 6, 2024, 3:42 PM EDT - 10 months ago

Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching

Jun 4, 2024, 4:05 PM EDT - 10 months ago

Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference

May 30, 2024, 4:00 PM EDT - 11 months ago

Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

May 7, 2024, 4:30 PM EDT - 11 months ago

Ultragenyx to Participate at Bank of America's 2024 Healthcare Conference

May 2, 2024, 8:28 PM EDT - 11 months ago

Ultragenyx Pharmaceutical, Inc. (RARE) Q1 2024 Earnings Call Transcript

May 2, 2024, 4:00 PM EDT - 1 year ago

Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update

Apr 30, 2024, 4:00 PM EDT - 1 year ago

Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease

Apr 25, 2024, 4:30 PM EDT - 1 year ago

Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update

Apr 12, 2024, 4:22 PM EDT - 1 year ago

Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome

Apr 12, 2024, 8:00 AM EDT - 1 year ago

Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting

Feb 15, 2024, 11:55 PM EST - 1 year ago

Ultragenyx Pharmaceutical, Inc. (RARE) Q4 2023 Earnings Call Transcript

Feb 15, 2024, 4:01 PM EST - 1 year ago

Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

Feb 8, 2024, 4:00 PM EST - 1 year ago

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update

Feb 6, 2024, 8:00 AM EST - 1 year ago

Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)

Feb 5, 2024, 4:05 PM EST - 1 year ago

Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome

Jan 25, 2024, 4:05 PM EST - 1 year ago

Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

Jan 7, 2024, 11:00 AM EST - 1 year ago

Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones

Jan 4, 2024, 8:00 AM EST - 1 year ago

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Jan 3, 2024, 8:00 AM EST - 1 year ago

Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome

Jan 2, 2024, 4:05 PM EST - 1 year ago

Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 18, 2023, 8:00 AM EST - 1 year ago

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)